Mechanism of Binding and Internalization of ICAM-1-Derived Cyclic Peptides by LFA-1 on the Surface of T Cells: A Potential Method for Targeted Drug Delivery

Pharmaceutical Research

Volumn 20, Issue 10, 2003, Pages 1523-1532

  Andersen, Meagan E ^a   Siahaan, Teruna J ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Binding; ICAM 1; Internalization; LFA 1; T cells; Targeted drug delivery

Indexed keywords

ANTIBODY; CD11 ANTIGEN; CYCLOPEPTIDE; FLUORESCEIN ISOTHIOCYANATE; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING SITE; CELL SURFACE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DELIVERY SYSTEM; EVALUATION; FLOW CYTOMETRY; FLUORESCENCE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INHIBITION KINETICS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN LOCALIZATION; TEMPERATURE DEPENDENCE;

CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MICROSCOPY, CONFOCAL; PEPTIDES, CYCLIC; RECEPTORS, ANTIGEN, T-CELL; SURFACE PLASMON RESONANCE; T-LYMPHOCYTES; TEMPERATURE; TIME FACTORS;

EID: 0142010621     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026188212126     Document Type: Article

References (41)

1. H. Yusuf-Makagiansar, M. E. Anderson, T. V. Yakovleva, J. S. Murray, and T. J. Siahaan. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med. Res. Rev. 22:146-167 (2002).
2. A. Grakoui, S. K. Bromley, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen, and M. L. Dustin. The immunological synapse: A molecular machine controlling T cell activation. Science 285:221-227 (1999).
3. M. L. Dustin. The immunological synapse. Arthritis Res. 4:S119-S125 (2002).
4. C. R. Monks, B. A. Freiberg, H. Kupfer, N. Sciaky, and A. Kupfer. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395:82-86 (1998).
5. B. Salomon and J. A. Bluestone. LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production. J. Immunol. 161: 5138-5142 (1998).
6. T. Labuda, J. Wendt, G. Hedlund, and M. Dohlsten. ICAM-1 costimulation induces IL-2 but inhibits IL-10 production in superantigen-activated human CD4+ T cells. Immunology 94:496-502 (1998).
7. M. Isobe, H. Yagita, K. Okumura, and A. Ihara. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 255:1125-1127 (1992).
8. K. Takazawa, Y. Hosoda, H. Bashuda, K. Senio, H. Yagita, T. Tamatani, M. Miyasaka, and K. Okumura. Synergistic effects of mycophenolate mofetil (MMF, RS-61443) and anti-LFA-1/ ICAM-1 monoclonal antibodies on the prolongation of heart allograft survival in rats. Transplant. Proc. 28:1980-1981 (1996).
9. F. C. Barouch, K. Miyamoto, J. R. Allport, K. Fujita, S. E. Bursell, L. P. Aiello, F. W. Luscinskas, and A. P. Adamis. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest. Ophthalmol. Vis. Sci. 41:1153-1158 (2000).
10. H. Moriyama, K. Yokono, K. Amano, M. Nagata, Y. Hasegawa, N. Okamoto, K. Tsukamoto, M. Miki, R. Yoneda, N. Yagi, Y. Tominaga, H. Kikutani, K. Hioki, K. Okumura, H. Yagita, and M. Kasug. Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 pathway. J. Immunol. 157: 3737-3743 (1999).
11. H. Schulze-Koops, P. E. Lipsky, A. F. Kavanaugh, and L. S. Davis. Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J. Immunol. 155:5029-5037 (1995).
12. A. F. Kavanaugh, L. S. Davis, R. I. Jain, L. A. Nichols, S. H. Norris, and P. E. Lipsky. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J. Rheumatol. 23:1338-1344 (1996).
13. A. B. Gottlieb, J. G. Krueger, K. Wittkowski, R. Dedrick, P. A. Walicke, and M. Garovoy. Psoriasis as a model for T-cell-mediated disease: Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch. Dermatol. 138:591-600 (2002).
14. K. Papp, R. Bissonnette, J. G. Krueger, W. Carey, D. Gratton, W. P. Gulliver, H. Lui, C. W. Lynde, A. Magee, D. Minier, J. P. Quellet, P. Patel, J. Shapiro, N. H. Shear, S. Kramer, P. Walicke, R. Bauer, R. L. Dedrick, S. S. Kim, M. White, and M. R. Garovoy. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J. Am. Acad. Dermatol. 45: 665-674 (2001).
15. S. A. Tibbetts, C. Chirathaworn, M. Nakashima, S. D. S. Jois, T. J. Siahaan, M. A. Chan, and S. H. Benedict. Peptides derived from ICAM-1 and LFA-1 modulate T cell adhesion and immune function in a mixed lymphocyte culture. Transplantation 68:685-692 (1999).
16. S. A. Tibbetts, S. D. S. Jois, T. J. Siahaan, S. H. Benedict, and M. A. Chan. Linear and cyclic LFA-1 and ICAM-1 peptides inhibit T cell adhesion and function. Peptides 21:1161-1167 (2000).
17. H. Yusuf-Makagiansar, I. T. Makagiansar, and T. J. Siahaan. Inhibition of the adherence of T-lymphocytes to epithelial cells by a cyclic peptide derived from inserted domain of lymphocyte function-associated antigen-1. Inflammation 25:203-214 (2001).
18. T. J. Siahaan, S. A. Tibbetts, S. D. S. Jois, M. A. Chan, and S. A. Benedict. Counter receptor binding domains that block or enhance binding to LFA-1 or ICAM-1. In P. T. P. Kaumaya and R. S. Hodges (eds.), Peptides: Chemistry, Structure and Biology. Mayflower Scientific, Kingswinford, England, 1996, pp. 792-793.
19. 2+ binding cyclic peptide derived from the alpha-subunit of LFA-1: Inhibitor of ICAM-1/LFA-1-mediated T-cell adhesion. J. Pept. Res. 53:18-29 (1999).
20. H. Yusuf-Makagiansar, I. T. Makagiansar, Y. Hu, and T. J. Siahaan. Synergistic inhibitory activity of α- and β-LFA-1 peptides on LFA-1/ICAM-1 interaction. Peptides 22:1955-1962 (2001).
21. A. M. Randi and N. Hogg. I-domain of beta 2 integrin lymphocyte function-associated antigen-1 contains a binding site for ligand intercellular adhesion molecule-1. J. Biol. Chem. 269:12395-12398 (1994).
22. R. N. Gursoy and T. J. Siahaan. Binding and internalization of an ICAM-1 peptide by the surface receptors of T cells. J. Pept. Res. 53:414-421 (1999).
23. M. L. Dustin, O. Carpen, and T. A. Springer. Regulation of locomotion and cell-cell contact area by the LFA-1 and ICAM-1 adhesion receptors. J. Immunol 148:2654-2663 (1992).
24. H. Yusuf-Makagiansar and T. J. Siahaan. Binding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cells. Pharm. Res. 18:329-335 (2001).
25. J. Bella, P. R. Kolatkar, C. W. Marlor, J. M. Greve, and M. G. Rossmann. The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin ligand. Proc. Natl. Acad. Sci. USA 95:4140-4145 (1998).
26. J. M. Casasnovas, T. Stehle, J. H. Liu, J. H. Wang, and T. A. Springer. A dimeric crystal structure for the N-terminal two domains of intercellular adhesion molecule-1. Proc. Natl. Acad. Sci. USA 95:4134-4139 (1998).
27. T. R. Gadek, D. J. Burdick, R. S. McDowell, M. S. Stanley, J. C. Marsters, Jr., K. J. Paris, D. A. Oare, M. E. Reynolds, C. Ladner, K. A. Zioncheck, W. P. Lee, P. Gribling, M. S. Dennis, N. J. Skelton, D. B. Tumas, K. R. Clark, S. M. Keating, M. H. Beresini, J. W. Tilley, L. G. Presta, and S. C. Bodary. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science 295:1086-1089 (2002).
28. E. D. Bell, A. P. May, and D. L. Simmons. The leukocyte function-associated antigen-1 (LFA-1)-binding site on ICAM-3 comprises residues on both faces of the first immunoglobulin domain. J. Immunol. 161:1363-1370 (1998).
29. D. A. Bleijs, M. E. Binnerts, S. J. van Vliet, C. G. Figdor, and Y. van Kooyk. Low-affinity LFA-1/ICAM-3 interactions augment LFA-1/ICAM-1-mediated T cell adhesion and signaling by redistribution of LFA-1. J. Cell Sci. 113: 391-400 (2000).
30. R. N. Gursoy, S. D. S. Jois, and T. J. Siahaan. Structural recognition of an ICAM-1 peptide by its receptor on the surface of T cells: conformational studies of cyclo (1,12)-Pen-Pro-Arg-Gly-Gly-Ser-Val-Leu-Val-Thr-Gly-Cys-OH. J. Pept. Res. 53:422-431 (1999).
31. S. D. S. Jois, D. Pal, S. A. Tibbetts, M. A. Chan, S. H. Benedict, and T. J. Siahaan. Inhibition of homotypic adhesion of T-cells: secondary structure of an ICAM-1-derived cyclic peptide. J. Pept. Res. 49:517-526 (1997).
32. X. Lu, Y. Sun, D. Shang, B. Wattam, S. Egglezou, T. Hughes, E. Hyde, M. Scully, and V. Kakkar. Evaluation of the role of proline residues flanking the RGD motif of dendroaspin, an inhibitor of platelet aggregation and cell adhesion. Biochem. J. 355:633-638 (2001).
33. A. McDowall, B. Leitinger, P. Stanley, P. A. Bates, A. M. Randi, and N. Hogg. The I-domain of integrin leukocyte function-associated antigen-1 is involved in a conformational change leading to high affinity binding to ligand intercellular adhesion molecule 1 (ICAM-1). J. Biol Chem. 273:27396-27403 (1998).
34. N. Hogg and B. Leitinger. Shape and shift changes related to the function of leukocyte integrins LFA-1 and Mac-1. J. Leukocyte Biol. 69:893-898 (2001).
35. Q. Ma, M. Shimaoka, C. Lu, H. Jing, C. V. Carman, and T. A. Springer. Activation-induced conformational changes in the I-domain region of lymphocyte function-associated antigen 1. J. Biol. Chem. 277:10638-10641 (2002).
36. G. Liu, J. R. Huth, E. T. Olejniczak, R. Mendoza, P. DeVries, S. Leitza, E. B. Reilly, G. F. Okasinski, S. W. Fesik, and T. W. von Geldern. Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties. J. Med. Chem. 44:1202-1210 (2001).
37. K. Last-Barney, W. Davidson, M. Cardozo, L. L. Frye, C. A. Grygon, J. L. Hopkins, D. D. Jeanfavre, S. Pav, C. Qian, J. M. Stevenson, L. Tong, R. Zindell, and T. A. Kelly. Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: Evidence for the allosteric inhibition of a protein-protein interaction. J. Am. Chem. Soc. 123:5643-5650 (2001).
38. L. A. Sklar and D. A. Finney. Analysis of ligand-receptor interactions with the fluorescence activated cell sorter. Cytometry 3: 161-165 (1982).
39. J. D. Chambers, S. I. Simon, E. M. Berger, L. A. Sklar, and K. E. Arfors. Endocytosis of beta 2 integrins by stimulated human neutrophils analyzed by flow cytometry. J. Leukocyte Biol. 53:462-469 (1993).
40. Z. Liao, L. M. Cimakasky, R. Hampton, D. H. Nguyen, and J. E. Hildreth. Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res. Hum. Retroviruses 17:1009-1019 (2001).
41. J. V. Fecondo, N. C. Pavuk, K. A. Silburn, D. M. Read, A. S. Mansell, A. W. Boyd, and D. A. McPhee. Synthetic peptide analogs of intercellular adhesion molecule 1 (ICAM-1) inhibit HIV-1 replication in MT-2 cells. AIDS Res. Hum. Retroviruses 9:733-740 (1993).